Global Healthcare CMO Market By Type (Pharmaceutical CMOs, and Medical Device CMOs), By Application (Medical, and Healthcare), By Region and Key Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2021-2030 (Includes Business Impact of COVID-19)

                                          
Report updated on 11th September, 2021: Global Healthcare CMO Market By Type (Pharmaceutical CMOs, and Medical Device CMOs), By Application (Medical, and Healthcare), By Region and Key Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2021-2030 (Includes Business Impact of COVID-19)
Trusted Business Insights has published a comprehensive market research report on, Global Healthcare CMO Market by Service Type (Medical Device CMOs and Pharmaceutical CMOs), By Application (Medical and Healthcare), and by Region -Global Forecast to 2030, which offers a holistic view of the global Healthcare CMO market through systematic segmentation that covers every aspect of the target market.

The global Healthcare CMO market is projected to be US$ 155,125.0 Mn in 2020 to reach US$ 361,905.3 Mn by 2030 at a CAGR of 8.8%.

A Contract Manufacturing Organization (CMO) is an organization or company that provides products or services to other pharmaceutical or medical device companies on a contract basis. Hence, a healthcare CMO allows any healthcare company to outsource the products of their requirement so the company can focus on the R&D, marketing and branding of their products. A rapid growth in the healthcare sector and pharmaceutical industries has resulted in the requirement of outsourcing of aspects required for the business. Majority of Contract Manufacturing companies started as the result of the failure of the newly established pharma companies that had expensive manufacturing facilities. This, promoted healthcare companies to utilize their resources in R&D and marketing and outsourcing the products from local manufacturers. Last few decades have witnessed the rise and evolution of several CMOs. The main factors responsible for this rapid growth of the CMO market are the economic nature of CMOs, growth in the healthcare sector and expansion of the product portfolio of the giant players of healthcare industries.

Earlier healthcare companies used to establish expensive and large facilities for the manufacturing of drugs and medical devices, but a number of failure stories of these facilities led to an increased demand for outsourcing of these products to reduce the risk factors for the manufacturers.


Global Healthcare CMO Market Revenue (US$ Mn), 2021 to 2030


However, a rise in the number of generic manufacturers and the evolution of emerging markets for the manufacturing of healthcare equipment and products might impose severe price pressure and competitive threats to the Healthcare CMOs. The regulations and taxes imposed by the local government bodies act hand in hand to intensify this pressure. Nonetheless, the healthcare contract manufacturing market that originally started and developed in the US and Western European countries is gradually being shifted to the emerging nations predominantly China and India. The low cost of labour and the easy availability of manufacturing facilities are the leading factors driving the growth of the CMO market in these regions.

Global Healthcare CMO market is segmented on the basis of service type, application and region. On the basis of service type, the market is segmented into Medical Device CMOs and Pharmaceutical CMOs. The Pharmaceutical CMOs segment accounts for the majority share, followed by Medical Device CMOs segment. On the basis of application, the market is segmented into Medical and Healthcare. The Healthcare segment accounts for a majority share in the global Healthcare CMO market.


Global Healthcare CMO Market by Service Type, 2018


On the basis of region, the market is segmented into North America, Europe, APAC, South America and Middle East Africa. North America accounts for the majority share in the global Healthcare CMO market. India is expected to register the highest growth rate over the forecast period.

The research report on the global Healthcare CMO market includes profiles of some of the major companies such as Piramal Enterprises Limited, Boehringer Ingelheim GmbH, Fareva, Thermo Fisher Scientific (Patheon), Lonza, Integer, Sanofi, Catalent, Inc.


Key Market Segments

By Type

  
Pharmaceutical CMOs
  
Medical Device CMOs

By Application

  
Medical
  
Healthcare


Key Market Players included in the report:


  
Accellent Inc.
  
Admedes Schuessler
  
Almac Group
  
Aurobindo Pharma Ltd.
  
Boehringer Ingelheim GmbH
  
Catalent Inc
  
Donatelle.
  
Dr. Reddy’s Laboratories Ltd.
  
DSM
  
FAMAR Health Care Services
  
Fareva
  
Greatbatch Inc.
  
Integer
  
Lonza Group
  
Memry Corporation
  
Patheon Inc.
  
Piramal Enterprises Limited
  
Recipharm AB (publ)
  
Royal DSM
  
Sanofi
  
Symmetry Medical Inc.
  
Teleflex MedOEM
  
Thermo Fisher Scientific (Patheon)


Below are the key development related to Healthcare CMO Market in 2020 and 2021.


June 2021: DFP Healthcare Acquisitions Corp. Announces Proposed Business Combination With The Oncology Institute.The Oncology Institute is the U.S. Market Leader in Value-Based Oncology Care. DFP Healthcare Acquisitions Corp (“DFP”) (NASDAQ: DFPH, DFPHW), a special purpose acquisition company sponsored by an affiliate of Deerfield Management Company, L.P. (“Deerfield”) and Richard Barasch, a veteran healthcare public company executive and investor, announced that it has entered into a definitive agreement for a business combination with The Oncology Institute ( “TOI” or “The Company”), the U.S. market leader in providing value-based oncology care. Following the business combination, DFP expects to be renamed The Oncology Institute and will remain listed on the NASDAQ stock market under new ticker symbol “TOI”. Source

November 2020: Aurobindo Pharma announces completion of acquisition. Aurobindo Pharma announced that the company has completed acquisition of MViyeS Pharma Ventures on 6 November 2020. On 17 October 2020, the company had informed about entering into a share purchase agreement to acquire 100% equity share capital of MViyeS Pharma Ventures (MViyeS). Before acquisition, MViyeS was holding 32.18% shareholding in Eugia Pharma Specialities, a joint venture company in which the company is holding the balance 67.82%. Now, both Eugia Pharma Specialities and MViyeS Pharma Ventures have become 100% subsidiaries of Aurobindo Pharma. Source

December 2020: Boehringer Ingelheim to Acquire Labor Dr. Merk & Kollegen to Strengthen its Next Generation Cancer Immunology Program. Boehringer Ingelheim has signed the agreement on the acquisition of all shares of Germany-based biotech company Labor Dr. Merk & Kollegen. Transaction expands Boehringer Ingelheim’s R&D and clinical manufacturing capabilities with a site focused predominantly on ATMP (Advanced Therapy Medicinal Products)-based cancer immunology treatments. Boehringer Ingelheim aims to accelerate the delivery of first-in-class immuno-oncology therapies to patients around the world. Boehringer Ingelheim announced the execution of the agreement on the acquisition of Labor Dr. Merk & Kollegen. The acquisition will enable Boehringer Ingelheim to further expand and accelerate its comprehensive program for the development of ATMP-based immuno-oncology therapies including the Vesicular Stomatitis Virus (VSV) with modified glycoprotein (GP) platform and cancer vaccines platforms. Labor Dr. Merk & Kollegen has outstanding experience in process development, manufacturing and analytical characterization in virology besides expertise in microbiology and cell culture. Labor Dr. Merk & Kollegen has already worked in close collaboration with Boehringer Ingelheim on viral-based therapy development since 2015. Source

January 2020: Galen buys Swedish firm POA Pharma. Privately-held pharma sales and marketing firm Galen has bought the boutique healthcare company, POA. Source